Sentinel Oncology present at the DDR Inhibitor Summit conference
Kyla Grimshaw, Director of Biology, is presenting a poster at the DDR Inhibitor Summit in Boston, MA, alongside colleagues from PharmaEngine.
The poster is titled ‘PEP07: A novel, brain penetrant oral Chk1 inhibitor for the treatment of AML and MCL’ and describes key preclinical data and clinical trial design for PEP07 (SOL578). The drug aims to begin patient recruitment for Phase 1 clinical studies in Q1 2023.
A copy of the poster can be found on our publications page.
